Drugs Made In America Acquisition Corp. (DMAA)
NASDAQ:DMAA
Want to see DMAA full AI Analyst Report?
Total Valuation
Drugs Made In America Acquisition Corp. has a market cap or net worth of $356.39M. The enterprise value is $356.72M.
Market Cap$356.39M
Enterprise Value$356.72M
Share Statistics
Drugs Made In America Acquisition Corp. has 33,717,144 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding33,717,144
Owned by Insiders―
Owned by Institutions0.94%
Financial Efficiency
Drugs Made In America Acquisition Corp.’s return on equity (ROE) is 0.03 and return on invested capital (ROIC) is -1.18%.
Return on Equity (ROE)0.03
Return on Assets (ROA)0.02
Return on Invested Capital (ROIC)-1.18%
Return on Capital Employed (ROCE)-0.01
Revenue Per Employee0.00
Profits Per Employee1.98M
Employee Count2
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Drugs Made In America Acquisition Corp. is 255.7. Drugs Made In America Acquisition Corp.’s PEG ratio is -0.08.
PE Ratio255.7
PS Ratio0.00
PB Ratio0.94
Price to Fair Value0.94
Price to FCF-404.04
Price to Operating Cash Flow-412.23
PEG Ratio-0.08
Income Statement
In the last 12 months, Drugs Made In America Acquisition Corp. had revenue of 0.00 and earned 5.94M in profits. Earnings per share was 0.19.
Revenue0.00
Gross Profit0.00
Operating Income-2.82M
Pretax Income5.94M
Net Income5.94M
EBITDA-2.82M
Earnings Per Share (EPS)0.19
Cash Flow
In the last 12 months, operating cash flow was -539.19K and capital expenditures 0.00, giving a free cash flow of -539.19K billion.
Operating Cash Flow-539.19K
Free Cash Flow-539.19K
Free Cash Flow per Share-0.02
Dividends & Yields
Drugs Made In America Acquisition Corp. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta<0.01
52-Week Price Change4.65%
50-Day Moving Average10.31
200-Day Moving Average―
Relative Strength Index (RSI)63.56
Average Volume (3m)49.15K
Important Dates
Drugs Made In America Acquisition Corp. upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Drugs Made In America Acquisition Corp. as a current ratio of 0.03, with Debt / Equity ratio of 0.00%
Current Ratio0.03
Quick Ratio0.03
Debt to Market Cap0.00
Net Debt to EBITDA<0.01
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Drugs Made In America Acquisition Corp. has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Drugs Made In America Acquisition Corp. EV to EBITDA ratio is -77.36, with an EV/FCF ratio of -404.03.
EV to Sales0.00
EV to EBITDA-77.36
EV to Free Cash Flow-404.03
EV to Operating Cash Flow-404.03
Balance Sheet
Drugs Made In America Acquisition Corp. has $6.14K in cash and marketable securities with $0.00 in debt, giving a net cash position of $6.14K billion.
Cash & Marketable Securities$6.14K
Total Debt$0.00
Net Cash$6.14K
Net Cash Per Share<$0.01
Tangible Book Value Per Share$11.07
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Drugs Made In America Acquisition Corp. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―